ArticleJournal of biomedical physics & engineering2025
Sonotherapy Using Folic Acid-Ag-Bi2O3 Nanocomposites in 2D and 3D Cultural C540 Melanoma Cells.
Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sonodynamic Therapy (SDT) is increasingly recognized as an innovative, non-invasive cancer modality in which low-intensity Ultrasound (U) energizes sonosensitizers, provoking a burst of Reactive Oxygen Species (ROS) that culminate in apoptotic destruction of tumor cells. Objective: Silver-bismuth oxide nanocomposites (AgB NCs) and their folic acid-functionalized counterparts (FAgB NCs) studied as sono-sensitizers for improving in treatment route of melanoma cancer. Material and Methods: In this experimental research, AgB NCs and FAgB NCs were synthesized via a green route using Results: (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) (MTT) assays on C540 melanoma cells revealed dose-dependent cytotoxicity, with F-AgBi NCs exhibiting significantly lower IC₅₀ values compared to AgB NCs. Upon U exposure, nanocomposites induced substantial ROS generation, mitochondrial dysfunction, and increased apoptosis, as verified by flow cytometry. Moreover, the FAgB NCs effectively suppressed cell migration and inhibited spheroid formation in 3D cultures, indicating potent antitumor activity in both monolayer and 3D models. Conclusion: These findings underscore the synergistic potential of folic acid-functionalized AgB nanocomposites as efficient sonosensitizers for targeted melanoma therapy. Their enhanced ROS-mediated cytotoxicity, combined with folate receptor-targeted delivery, supports their application in advanced nanomedicine and SDT-based cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.